Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Central nervous system diseases

Neuroscience

Neuroscience Today—March 25, 2026

This week’s Neuroscience update highlights commercial launches, manufacturing…

Neuroscience

Neuroscience Today — December 17, 2025

This week’s Neuroscience update features regulatory decisions, pipeline…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Axoft $55 million Series A
Lucid Diligence Brief: Greywolf Therapeutics and Genomics strategic partnership
Public Health Today—May 1, 2026
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration for cancer trispecific HH160
Vaccines Today—April 30, 2026

Tags

ai in oncology astrocytes Biorep Technologies BMJ cancer care cancer vaccines Celea Therapeutics CLN2 disease Clostridioides Difficile Infection competitive advantage Debio 4126 delivery technology Diffuse large B-cell lymphoma Drug Development Innovation EGFR employer benefits Ensitrelvir Epithelial biology Eptinezumab FNIH Biomarkers Consortium gene therapy manufacturing gynecologic oncology HeartFlow Hematologic malignancies hip bone mineral density Hotwire HSA HSV JPM 2026 Karolinska Institutet Kedrion LNP Lung Adenocarcinoma neuroprotection NIHR Southampton Omisirge Pain Pediatric obesity pregnancy Relmada Therapeutics royalties Tecvayli therapeutic index Thermo Fisher threads

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Axoft $55 million Series A
Lucid Diligence Brief: Greywolf Therapeutics and Genomics strategic partnership
Public Health Today—May 1, 2026
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration for cancer trispecific HH160
Vaccines Today—April 30, 2026

TAGS

ai in oncology astrocytes Biorep Technologies BMJ cancer care cancer vaccines Celea Therapeutics CLN2 disease Clostridioides Difficile Infection competitive advantage Debio 4126 delivery technology Diffuse large B-cell lymphoma Drug Development Innovation EGFR employer benefits Ensitrelvir Epithelial biology Eptinezumab FNIH Biomarkers Consortium gene therapy manufacturing gynecologic oncology HeartFlow Hematologic malignancies hip bone mineral density Hotwire HSA HSV JPM 2026 Karolinska Institutet Kedrion LNP Lung Adenocarcinoma neuroprotection NIHR Southampton Omisirge Pain Pediatric obesity pregnancy Relmada Therapeutics royalties Tecvayli therapeutic index Thermo Fisher threads

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy